Point-of-care antigen test earns FDA emergency use authorization

Jul 07, 2020 - 05:02 PM
FDA product update

The Food and Drug Administration Monday authorized the emergency use of the BD (Becton Dickinson) Veritor System for Rapid Detection of SARS-CoV-2.

The test is the second antigen diagnostic to earn an emergency use authorization from FDA and can be used in patient care settings approved for CLIA high or moderate complexity or waived testing.

However, the test’s emergency use is limited to authorized laboratories using the BD Veritor Plus Analyzer Instrument.

Related News Articles

Headline
FDA issues guidance on wellness products, clinical decision support software
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
CDC report finds COVID-19 vaccine for children reduced chances of ED, urgent care visits
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
AHA responds to FDA request for information on AI-enabled medical devices
The AHA provided recommendations to the Food and Drug Administration Dec. 1 in response to a request for information on the measurement and evaluation of…
Headline
Permanent recall issued for Baxter ventilation system
The Food and Drug Administration has identified a Class I recall of Baxter Life2000 Ventilation Systems due to a cybersecurity issue discovered through…
Headline
Recall issued for mislabeled potassium chloride
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
CDC adopts ACIP recommendations for COVID-19, chickenpox vaccines
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…